In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...
24/7 Wall St. on MSN23h
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street ExpertBillionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...
Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...
Hosted on MSN6d
Biogen Announces New Chief Accounting Officer AppointmentBiogen ( ($BIIB) ) has issued an update. On January 13, 2025, Biogen Inc. announced the appointment of Sean Godbout as Vice ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Hosted on MSN5d
Biogen's Quarterly Earnings Preview: What You Need to KnowBiogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback